Mumbai, October 20 (Udaipur Kiran): Shares of Alembic Pharmaceuticals Limited gained over 1% in Monday’s trade after the company received final approval from the U.S. Food and Drug Administration (USFDA) for its Triamcinolone Acetonide Injectable Suspension USP.
The stock was trading at Rs. 947.55, up Rs. 10.05 or 1.07% from its previous close of Rs. 937.50 on the BSE. It opened at Rs. 984.95, touching an intraday high of Rs. 984.95 and a low of Rs. 941.90, with 383 shares changing hands so far. The company’s market capitalisation stands at Rs. 18,646.96 crore.
In the past 52 weeks, the stock has touched a high of Rs. 1,186.00 (October 21, 2024) and a low of Rs. 725.60 (March 3, 2025). The promoters hold 69.74% stake, while institutional investors and non-institutional investors own 20.35% and 9.92%, respectively.
The USFDA approval covers Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL Single-Dose Vials, and 200 mg/5 mL & 400 mg/10 mL (40 mg/mL) Multiple-Dose Vials. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to Kenalog-40 Injectable Suspension, the reference listed drug of Bristol-Myers Squibb Company.
This injectable formulation is used in treating a range of autoimmune, inflammatory, and other conditions where oral therapy is not suitable.
With this latest approval, Alembic Pharmaceuticals now holds a total of 227 ANDA approvals from the USFDA, including 206 final approvals and 21 tentative approvals, reflecting its strong position in the international generics market.
Alembic Pharmaceuticals, a vertically integrated pharmaceutical company, is engaged in the manufacturing and marketing of Indian formulations, international generics, and Active Pharmaceutical Ingredients (APIs).
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
